One year does not a trend make, but it does look like prices for health insurance under Obamacare next year will decline, on average. Ezra Klein, over at Vox.com, produced a nice picture of these prices: Who knows: in the … Continue reading →
<p style="line-height: 19.0400009155273px;"><span style="line-height: 19.0400009155273px;">On August 30, 2014, cardiovascular drug researchers managing the PARADIGM-HF Study and its Committees announced that they were terminating their Phase III trial of LCZ696 because of observed “<a href="http://www.dailymail.co.uk/health/article-2738993/Remarkable-new-heart-drug-cut-deaths-fifth-available-early-year.html">overwhelming benefit</a>.” As reported in The Daily Mail: “Thousands of lives could be saved by a new drug for heart failure that researchers claim outperforms the current best treatments. … Research on more than 8,000 patients found that it saved 20 per cent more lives than the current ‘gold standard’ treatment – the ACE inhibitor enalapril.” The <a href="http://www.reuters.com/article/2014/08/30/us-health-heart-novartis-idUSKBN0GU0CQ20140830">findings were announced</a> at the annual meeting of the European Society of Cardiology and published the same day in the <a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1409077">The New England Journal of Medicine</a>. In a news release, the Switzerland-based Novartis International AG – the drug manufacturer sponsor – said that it would submit an FDA application to market the drug in the US by the end of 2014. Novartis anticipates <a href="http://www.novartis.com/newsroom/media-releases/en/2014/1852531.shtml">submitting a similar application</a> to the European Union by early 2015.</span></p>
<p style="line-height: 19.0400009155273px;">Analysts say “that [the new drug] might <a href="http://www.nytimes.com/2014/08/31/business/new-novartis-drug-shows-striking-efficacy-in-treating-heart-failure.html">cost $7 a day in the United States</a>, or about $2,500 a year. Existing [standard] drugs are generic, costing as little as [$48 a year] … .”</p>
<p style="line-height: 19.0400009155273px;"><strong style="color: #34405b; font-family: Arial, Helvetica, sans-serif; font-size: 12px; line-height: 20px;">The Alden March Bioethics Institute offers a Master of Science in Bioethics, a Doctorate of Professional Studies in Bioethics, and Graduate Certificates in Clinical Ethics and Clinical Ethics Consultation. For more information on AMBI’s online graduate programs, please visit our <a style="text-decoration: underline; color: #000099;" href="http://www.amc.edu/Academic/bioethics/index.cfm">website</a>.</strong></p>
On November 7, 2014, Wolfson Children’s Hospital, in partnership with the University of North Florida and the Florida Bioethics Network, presents the Seventh Annual Pediatric Bioethics Conference.
Alissa Hurwitz Swota, PhD
University of North Florida and Wolfson Children’s Hospital, Jacksonville, FL
Wolfson Lecture: Ethical Dilemmas in Pediatric Nursing Administration
Veronica Scott-Fulton, DNP, MPH, RN, NEA-BC
Vice President, Operations & Patient Care Services
Wolfson Children’s Hospital
Ethical and Clinical Challenges in Caring for Children with Cancer in the Era of Chemotherapy Drug Shortages: The Not so Good, the Bad, and the Ugly
Yoram Unguru, MD, MS, MA
Attending Physician, Division of Pediatric Hematology/Oncology, The Herman and Walter Samuelson Children’s Hospital at Sinai Core Faculty, Johns Hopkins Berman Institute of Bioethics; Assistant Professor, Johns Hopkins University School of Medicine
Living with Illness: A Sibling Perspective
Moderator: Kelly Komatz, MD, MPH, FAAP, FAAHPM
Assistant Professor, UF COM Jacksonville, Department of Pediatrics/Community Pediatrics
Conflict Resolution in Healthcare: Beyond Bioethics Mediation
Haavi Morreim, JD, PhDProfessor, Department of Internal Medicine, College of Medicine, University of Tennessee; Principal, ADR Institute, LLC
Can We Reasonably Hope to Transform Unreasonable Hopes?
Ralph Baergen, PhD, MPH
Professor of Philosophy, Idaho State University
Child Abuse: Working with Parents who may have put their Child in the Hospital
Kathleen Dully, MD
Medical Director, First Coast Child Protection Team
Shortly after I submitted my last post “Limning Autonomy in Surgery” I was contacted by the blog editor letting me know that I had made a typo in my title and that he would go ahead and correct it for me. The problem is that I really do mean to use the word “limn.” When I was at Wheaton College a couple of my professors… // Read More »
The Wellcome Trust has awarded a Senior Investigator Award in the Medical Humanities, entitled: “Interventions at the End of Life – Social, Comparative and Historical Analysis to Promote Global Improvement.”
The research involves a rigorous assessment of the world’s end of life care needs – and will propose strategies for improvement. It will also seek to generate more sustainable and appropriate end of life interventions, across various cultures and settings.
David Clark at the University of Glasgow more fully describes the project here.
The Disability Rights Legal Center part of the Public Interest Law Center of Loyola Law School Los Angeles has announced Kathryn L. Tucker, Esq., as its new Executive Director and Director of Advocacy and Legal Affairs.
Tucker joins DRLC from the national nonprofit organization Compassion & Choices, where she worked to improve patient rights and choice at the end of life as Director of Advocacy and Legal Affairs for two decades.
Tucker also served as lead counsel in two landmark end of life care cases before the United States Supreme Court, which established the right of dying patients to aggressive pain management. Her work has furthered the rights of patients in many states to better end of life care. She helped successfully defend Oregon’s Death with Dignity Act and was instrumental in successful campaigns to pass similar laws in other states.
Tucker has held a faculty appointment at Loyola for a number of years, teaching “Law, Medicine and Ethics at the End of Life.” Her new position will enable her to continue work on behalf of patients with serious illness, as DRLC includes the Cancer Legal Resource Center and the HIV Law and Policy Project.
Given the historic tension between end of life choice advocates and much of the Disability Advocacy community, the DRLC Board’s selection of Tucker is impressive and commendable. It is also smart. Tucker has two decades of experience in moving a multidimensional advocacy agenda forward for a social change movement. Her work involved state and federal impact litigation as well as state and federal legislative work. She is known for creative aggressive advocacy and achieving outstanding results. Selecting her as Executive Director, positions DRLC to be a leader in the Disability community.
Germany unveiled a World War II memorial this week. It is the first to commemorate those with medical problems who were deemed unworthy of life (Lebensunwertes Leben) and were exterminated by the Nazi regime. The memorial wall has been built at Tiergartenstraße 4 in Berlin, not only the site of the “Charitable Foundation for Cure and Institutional Care” but also the address that gave the German… // Read More »
AARP is hosting a major convention this weekend in San Diego. But AARP is excluding participation of right to die groups.
The organization rejected the request of the Final Exit Network have a booth at the AARP Expo in San Di…
In my last post I spoke about an ethical issue mentioned in passing in a book that examined reproductive medicine from the perspective of organizational theory: that in this age of evidence-based medicine some of the most vital decisions—who lives and who does not—are based primarily on subjective grounds. A second issue mentioned in the book that I found greatly disturbing was that the use… // Read More »